Communiqués Actinium Pharmaceuticals, Inc.

Actions

ATNM

US00507W2061

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX Autres places de cotation 16:43:20 23/07/2026			Varia. 5j.	Varia. 1 janv.
0,8930 ^USD	-0,78%		+1,00%	-33,90%

03/06	Actinium Pharmaceuticals présente de nouvelles données sur l'ATNM-400 démontrant une activité puissante dans des modèles de cancer de la prostate résistants aux trois inhibiteurs des récepteurs aux androgènes approuvés	CI
01/06	Actinium Pharmaceuticals, Inc. nomme Steffen Heeger au poste de Chief Medical Officer	CI

Communiqués

03/06	Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer	PR
03/06	Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Models	PR
01/06	Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development	PR
01/06	Actinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates	PR
29/05	Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs	PR
29/05	Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice	PR
08/05	Actinium: Q1 Earnings Snapshot	AQ
06/05	Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization	PR
22/04	Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting	PR
22/04	Actinium Pharmaceuticals : Preclinical Development of ATNM-400, a First-in-Class Actinium-225 Radioconjugate with Pan-Tumor Efficacy in Solid Tumors	PU
22/04	Actinium Pharmaceuticals : Actimab-A, a CD33-Targeted Actinium-225 Radioconjugate, Drives Mutation-Agnostic Anti-Leukemic Activity and Synergizes with Standard Therapies in AML Through Transcriptional Reprogramming	PU
06/04	Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting	PR
31/03	Actinium: Q4 Earnings Snapshot	AQ
17/02	Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting	PR
12/01	Actinium Pharmaceuticals : Pioneering Differentiated Radiotherapies for Patients with Unmet Needs	PU
12/12	Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025	PR
12/12	ATNM-400 SABCS: Anti-Tumor Activity of ATNM-400, a First-in-class Actinium-225 Antibody Radioconjugate, in Hormone-Positive, Triple-Negative, Tamoxifen-Resistant and Trastuzumab-Resistant Breast Cancer Models	PU
11/12	Actinium Pharmaceuticals Advances Trop-2 Targeted Alpha Radiotherapy Into Phase 1/2 Trials in the U.S. and Australia	AQ
10/12	Actinium Pharmaceuticals (NYSEAMERICAN: ATNM) Begins European Phase 1 Trial of Nectin-4 Targeted Alpha Therapy for Multiple Solid Tumors	AQ
09/12	Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) Advances ATNM-400 Targeting STEAP-1 Across Prostate, Breast, and Lung Cancer	AQ
08/12	ATNM-400 Targets B7-H3 and Is Being Studied in a Phase 1 Clinical Trial in South Africa	AQ
08/12	Actinium Pharmaceuticals Advances ATNM-400 B7-H3 Candidate Into Phase 1 Clinical Trial in South Africa	AQ
01/12	Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium	PR
17/11	The Race for the Global Radiotherapy Cancer Market; Actinium Pharmaceuticals' (ATNM) Big Bet	NE
14/11	Actinium: Q3 Earnings Snapshot	AQ